Levosimendan是一种钙增敏剂，通过钙离子浓度依赖性方式与心肌肌钙蛋白C结合，增强心肌收缩力。
| 英文别名 (English Synonym) | Levosimendan |
| 中文名称 (Chinese Name) | 左西孟旦 |
| 靶点 (Target) | Calcium Channel |
| 通路 (Pathway) | Membrane Transporter/Ion Channel |
| CAS号 (CAS NO.) | 141505-33-1 |
| 分子式 (Formula) | C14H12N6O |
| 分子量 (Molecular Weight) | 280.28 |
| 纯度 (Purity) | ≥98% |
| 溶解性 (Solubility) | 溶于DMSO |
-25~-15℃保存，有效期3年
[1] Nieminen MS, Fruhwald S, Heunks LM, Suominen PK, Gordon AC, Kivikko M, Pollesello P. Levosimendan: current data, clinical use and future development. Heart Lung Vessel. 2013;5(4):227-45. PMID: 24364017; PMCID: PMC3868185.[2]Papp Z, Édes I, Fruhwald S, De Hert SG, Salmenperä M, Leppikangas H, Mebazaa A, Landoni G, Grossini E, Caimmi P, Morelli A, Guarracino F, Schwinger RH, Meyer S, Algotsson L, Wikström BG, Jörgensen K, Filippatos G, Parissis JT, González MJ, Parkhomenko A, Yilmaz MB, Kivikko M, Pollesello P, Follath F. Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol. 2012 Aug 23;159(2):82-7. doi: 10.1016/j.ijcard.2011.07.022. Epub 2011 Jul 23. PMID: 21784540.
